|By PR Newswire||
|February 12, 2014 08:31 AM EST||
GARDEN CITY, N.Y., Feb. 12, 2014 /PRNewswire/ -- Millennium HealthCare Inc. (OTCBB: MHCC) today announced that its subsidiary, Millennium Medical Devices LLC, through a signed exclusive agreement with CDx Diagnostics, will begin its rollout and distribution of the OralCDx brush biopsy test kit. OralCDx is a non-invasive test that is used to test the small white and red tissue spots commonly found in the mouth to rule out precancerous change. The test has previously been available to dentists nationwide, and has already resulted in the prevention of thousands of oral cancers. Through this exclusive collaboration, Primary Care Physicians will be able to administer this test to their patients.
"We are pleased to add the OralCDx test kit to distribute through our Medical Device business," said Dominick Sartorio, CEO of Millennium. "There are over 250,000 primary care physicians in the United States who could utilize the OralCDx test kit as a routine procedure in their practice."
"Over 12 years of oral cancer prevention data from hundreds of thousands of US patients, coupled with the recent addition of molecular biomarkers to our laboratory analysis, make this a perfect time to rollout this lifesaving test to primary care physicians," says Mark Rutenberg, CEO of CDx Diagnostics. "This is the beginning of an exciting opportunity. OralCDx testing administered by dentists has already resulted in the detection of well over 10,000 precancers while they were still harmless. Through Millennium's efforts to add primary care physicians, nurse practitioners, and physician's assistants into this program, many more lives will clearly be saved."
The Oral Cancer Foundation aired a nationwide public service announcement (PSA) partnering with several known celebrities including Michael Douglas, who discussed the importance of early oral cancer detection. (Link to video: http://www.youtube.com/watch?v=L_3S_93_jGE)
Oral cancer claims about as many American lives as melanoma, twice as many as cervical cancer, and is as common as all of the major forms of leukemia combined. For reasons that are not completely understood this disease is also now rising among the former low risk groups of women, young people and non-smokers.
According to the Oral Cancer Foundation, close to 42,000 Americans will be diagnosed with oral and oropharyngeal cancer this year. The disease will cause over 8,000 deaths, killing roughly one person every hour, every day. Of those 42,000 newly diagnosed individuals, only slightly more than half will be alive in five years due to late detection, a number that has not significantly improved in decades. The death rate for oral cancer is higher than that of other cancers that we hear about routinely, such as cervical cancer, Hodgkin's lymphoma, laryngeal cancer, cancer of the testes, and endocrine system cancers such as thyroid, or skin cancer (malignant melanoma).
David Perry, President of Millennium Medical Devices, commented, "The OralCDx brush biopsy is very accurate and has been the subject of well controlled, randomized, clinical trials. In every study in which the same lesion was simultaneously tested with both OralCDx and a scalpel biopsy, OralCDx was shown to be at least as sensitive to a scalpel biopsy in identifying dysplasia or cancer."
About Millennium HealthCare Inc.
Millennium HealthCare Inc. through its wholly owned operating subsidiaries provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection. The Company also provides advanced billing and coding services and practice development and management services.
About CDx Diagnostics
CDx Diagnostics (www.CDxDiagnostics.com) is the leader in the detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. The CDx tests are primarily used to help prevent cancer before it can start by identifying still-harmless dysplasia (precancer), and are also used to identify early stage cancers when they can be most easily cured. Clinicians use CDx patented minimally invasive brush biopsy instruments to collect a wide-area, full thickness tissue specimen of a suspect lesion. This unique tissue specimen is then subjected to specialized, three-dimensional computer-assisted laboratory analysis. These life saving tests are nationally available to gastroenterologists, otolaryngologists, oral surgeons, periodontists, and dentists.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains certain statements that may constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Forward-looking statements are identified by such words and phrases as "we expect," "expected to," "estimates," "estimated," "current outlook," "we look forward to," "would equate to," "projects," "projections," "projected to be," "anticipates," "anticipated," "we believe," "could be," and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. Because they are forward-looking, they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
SOURCE Millennium HealthCare Inc.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Dec. 10, 2016 11:45 PM EST Reads: 1,794
Dec. 10, 2016 11:15 PM EST Reads: 1,218
Dec. 10, 2016 10:15 PM EST Reads: 2,072
Dec. 10, 2016 09:15 PM EST Reads: 1,354
Dec. 10, 2016 07:30 PM EST Reads: 1,820
Dec. 10, 2016 07:00 PM EST Reads: 4,156
Dec. 10, 2016 06:45 PM EST Reads: 1,105
Dec. 10, 2016 06:30 PM EST Reads: 1,972
Dec. 10, 2016 06:30 PM EST Reads: 1,551
Dec. 10, 2016 06:30 PM EST Reads: 1,034
Dec. 10, 2016 06:15 PM EST Reads: 1,096
Dec. 10, 2016 05:30 PM EST Reads: 1,012
Dec. 10, 2016 05:15 PM EST Reads: 2,384
Dec. 10, 2016 05:15 PM EST Reads: 1,426
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
Dec. 10, 2016 04:30 PM EST Reads: 1,374